Digital health · Medical search and AI answers
MediSearch
A search engine that answers medical questions from published sources, built by two founders and backed by Y Combinator. It is fast, widely used by its own count, and so far tested by outsiders on only a narrow set of cases.
Eight surgeons, six answers
Eduard Oravkin was facing a second knee surgery in December. He went to see eight surgeons in four countries and came away with six different surgical options.
The company’s own launch post tells it this way: “He had no idea which opinion to trust, so he turned to researching online.” What he found is the problem MediSearch says it exists to fix.
The problem
The founders sort existing health information into three piles. Sites such as WebMD and Healthline are unable to give direct answers. General chatbots and health blogs are untrustworthy. PubMed papers are too technical for most readers. That list is the company’s framing, not a market study, but it describes a real gap between a search box and a journal article.
MediSearch’s answer is retrieval first. The system searches a curated set of medical sources, writes a direct answer with citations, and says so when it cannot find credible support. A patient blogger who reviewed the product in December 2024 described the sourcing as a core difference from a general chatbot. She disclosed that the post was sponsored by MediSearch and that the founder had given her access to the Pro version, so her review is treated here as company-adjacent.
Founders
The company was founded by Eduard Oravkin and Michal Pándy. A Crunchbase profile says Oravkin has roots at the University of Oxford. Nothing verifiable was found on Pándy’s background beyond his co-founder title, and the profile pages that might describe it were not readable.
Data aggregators disagree on where the company sits. GetLatka lists London, and the brief for this profile says London. PitchBook, Tracxn and Crunchbase list San Francisco, which is the usual base for a Y Combinator company. The founders’ own pages do not settle it.
Timeline
PitchBook records an accelerator entry in January 2023 and an early stage venture deal in September 2023. Y Combinator describes the company as S23, meaning Summer 2023, and the two dates do not line up neatly. The launch post says usage grew 30x after the company joined Y Combinator, a figure no outside source has checked.
By December 2024 the company had launched MediSearch Pro on web, iOS and Android, claiming 94.2% on the United States Medical Licensing Examination sample questions. In December 2025 it released MediSearch Max and said the model scored 53.3% on HealthBench Hard, OpenAI’s benchmark for difficult medical cases, ahead of GPT-5 and GPT-4o. Y Combinator repeated that claim on its social accounts. The company also sells an API, and its developer page lists clinical decision support, consumer question answering and a medical judge use case, with HIPAA compliance and SOC 2 Type 1 stated.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| USMLE accuracy | 94.2% on the USMLE sample examination, called the most accurate publicly available medical search engine at launch in December 2024. No independent replication found. | Company-stated |
| HealthBench Hard | 53.3% for MediSearch Max, said to beat GPT-5 and GPT-4o (December 2025). Repeated by Y Combinator. No independent replication found. | Company-stated |
| Outside evaluation | A medRxiv preprint from September 2025 had four external clinicians rate four agents on 128 question and answer pairs from four vignettes. Medisearch scored 71.1% satisfaction, the lowest of the agents, against 92.9% for ArkangelAI-Deep and 83.6% for OpenEvidence. It was the fastest at a median of 18 seconds. The authors belong to Arkangel AI, a competitor, and the vignettes were few. | Independent, competitor-authored |
| Claim versus evaluation | The company’s exam score is high while the outside vignette study ranks it last of the agents tested. The tests measure different things, but the two results do not sit easily together. | Differs |
| Users | “Over a million users” appears in a sponsored review, repeating the company. No usage audit found. | Company-stated |
| UK company records | Two Companies House entries named Medisearch Limited exist. One was incorporated in 2021 and dissolved in March 2025, the other in 2008. Neither shows the founders as officers, so neither is used. | No match |
| SEC Form D | None tied to MediSearch. A Form D returned in the search belongs to Medivis, Inc., an unrelated New York company. | Not found |
| API customers | API offered since the early launch. No customer is named on the developer page or in any source found. | Not found |
Read plainly: MediSearch has real distribution, a stated benchmark record and a credible investor list, but the public trail is thin. The only outside test found is small, run by a rival, and unflattering. The strongest numbers are the company’s own.
What to watch
- A larger independent test, ideally with the questions and scoring published, that includes the current Max model. The preprint tested the standard product.
- Named API customers, and evidence for the security certifications the developer page states.
- A filed Form D or a company announcement that confirms the size and date of any financing.
- A clear statement of where the company is legally based.
In their words
“You know how when you google stuff about your health, you always end up getting diagnosed with some deadly disease by an SEO-optimized health blog?”
MediSearch founders, Y Combinator launch post · Company post
“He had no idea which opinion to trust, so he turned to researching online.”
MediSearch founders on Eduard Oravkin, Y Combinator launch post · Company post
“Since joining YC, the usage of MediSearch has grown 30x, validating that we are solving a real problem.”
MediSearch founders, Y Combinator launch post · Company post
“Several YC companies recently reached out whether we offer MediSearch through an API. So now we do.”
MediSearch founders, Y Combinator launch post · Company post
“There is a huge leap in the quantity and quality of information. Stunning.”
Neurologist beta tester, unnamed, quoted in the December 2025 Max announcement · Company post
“MediSearch on the other hand, cites and links to all sources it derived its answers from.”
Sheryl Chan, A Chronic Voice, December 2024, sponsored review · Sponsored
“ArkangelAI-Deep and OpenEvidence consistently outperformed others, while Medisearch and GPT-Regular had significant limitations.”
Castano-Villegas et al., medRxiv preprint, 2025 · Independent
Related companies
Sources
- Public recordCompanies House, Medisearch Limited 13718562, overview, officers and filing history
- Public recordCompanies House, Medisearch Limited 06572621, officers
- Public recordSEC Form D, Medivis, Inc. (unrelated filer, checked and excluded)
- IndependentArkangel AI, OpenEvidence, ChatGPT, Medisearch: are they objectively up to medical standards?
- CompetitorSummary of the Mayo Clinic Proceedings: Digital Health version of the study
- IndependentMediSearch 2026 company profile, valuation, funding and investors
- IndependentMediSearch company profile and team
- IndependentMediSearch Raises $500K Seed Round
- IndependentMediSearch revenue 2024, estimated
- IndependentMediSearch AI: A Deep Dive into the Future of Medical Information
- IndependentEduard Oravkin, Crunchbase person profile
- IndependentPortfolio company post on MediSearch
- SponsoredMediSearch Review: A Medical AI Search Engine for Patients, Clinicians and Medical Writers
- CompanyLaunch YC: MediSearch, AI search engine for trustworthy medical information
- CompanyMediSearch company page and MediSearch Pro launch
- CompanyMediSearch Max announcement, HealthBench Hard 53.3%
- CompanyMediSearch API developer page
- CompanyMediSearch home page
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
